#USA #New York #Levi & Korsinsky #Revance Therapeutics #RVNC

Urgent Notice for Revance Therapeutics Shareholders

As a crucial date approaches, all shareholders of Revance Therapeutics, Inc. are urged to get in touch with the law firm of Levi & Korsinsky, LLP. Investors must act before March 4, 2025, to discuss their rights in light of a class action lawsuit filed against the company (NASDAQ: RVNC). This alert serves as a timely notification for all those affected by the alleged securities fraud that occurred within a specific period.

Class Action Lawsuit Details

The class action lawsuit seeks to recover losses for investors adversely impacted between February 29, 2024, and December 6, 2024. Shareholders are encouraged to gather information regarding the case, which points towards serious allegations of securities fraud against Revance. Specifically, the company is accused of breaching its distribution agreement with Teoxane, which granted them exclusive rights to market and distribute Teoxane’s dermal fillers.

The lawsuit highlights multiple claims, including:

• - Material breach of contract, leading to increased litigation risk and reputational damage to Revance.
• - Complications arising that could potentially delay and/or amend the tender offer for the company's securities.
• - Misleading public statements that could have misinformed investors about the company's actual position.

Important Next Steps

If you suffered financial losses as a result of your investment in Revance during the relevant time frame, it’s pivotal that you reach out to the firm as soon as possible. You have until March 4, 2025, to apply for lead plaintiff status, although this step is not necessary for participating in any potential recovery. The law firm ensures that there are no out-of-pocket costs involved for class members, making participation risk-free.

Why Choose Levi & Korsinsky

Levi & Korsinsky has built a robust reputation in the field of securities litigation over the past two decades. Their track record includes securing hundreds of millions in settlements for aggrieved shareholders. With a dedicated team of over 70 professionals, they are well-equipped to support clients in complex legal battles. For seven consecutive years, the firm has earned a place in the Top 50 Report as one of the leading securities litigation firms in the United States according to ISS Securities Class Action Services. This extensive expertise makes them a reliable partner for investors navigating legal challenges.

How to Contact Levi & Korsinsky

Interested shareholders can either submit a form available through the law firm’s website for more details (link provided in the original announcement) or initiate direct contact with Joseph E. Levi, Esq. The contact can be established through email or phone:

• - Email: [email protected]
• - Phone: (212) 363-7500

Investors are strongly advised to consider this opportunity to affirm their rights and potentially recover losses due to the alleged misconduct of Revance Therapeutics. By acting before the March 2025 deadline, shareholders can secure legal support to address their grievances effectively.